false 0001625101 0001625101 2023-09-10 2023-09-10
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): September 10, 2023
 
Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
     
Delaware
001-37744
46-5696597
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
3957 Point Eden Way 
Hayward, California 94545
(Address of Principal Executive Offices) (Zip Code)
 
510-906-4600
(Registrant’s Telephone Number, Including Area Code)
 
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share
PLSE
The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On September 10, 2023, the Board of Directors of Pulse Biosciences Inc., a Delaware corporation (the “Company”), upon the recommendation of its Compensation Committee, approved one-time cash bonuses, each in the amount of $300,000, payable to Mr. Kevin Danahy, the Company’s President and Chief Executive Officer, and to Mr. Darrin Uecker, its Chief Technology Officer, for their leadership and the Company’s programmatic achievements in 2023. The parties have agreed that each of these bonuses will be credited against any future bonuses otherwise payable to Messrs. Danahy and Uecker, pursuant to the Company’s 2023 bonus plan and their employment agreements with the Company.
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
PULSE BIOSCIENCES, INC.
  
     
     
Date: September 12, 2023
By:
/s/ Kevin P. Danahy
  
   
Kevin P. Danahy
  
   
President and Chief Executive Officer
(Principal Executive and Principal Financial Officer)
  
 
 
v3.23.2
Document And Entity Information
Sep. 10, 2023
Document Information [Line Items]  
Entity, Registrant Name Pulse Biosciences, Inc.
Document, Type 8-K
Document, Period End Date Sep. 10, 2023
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-37744
Entity, Tax Identification Number 46-5696597
Entity, Address, Address Line One 3957 Point Eden Way 
Entity, Address, City or Town Hayward
Entity, Address, State or Province CA
Entity, Address, Postal Zip Code 94545
City Area Code 510
Local Phone Number 906-4600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol PLSE
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001625101
Pulse Biosciences (NASDAQ:PLSE)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Pulse Biosciences.
Pulse Biosciences (NASDAQ:PLSE)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Pulse Biosciences.